Based on 1 Customer Validation
L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 50-81-7
- Formula: C6H8O6
- Molecular Weight:176.12
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: L-ASA
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
| CFPAC-1 | IC50 |
>100 μM
Compound: L-ASA
|
Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
| Erythrocyte | EC50 |
119.87 μg/mL
Compound: Ascorbic acid
|
Antioxidant activity in erythrocytes assessed as inhibition of hemolysis
Antioxidant activity in erythrocytes assessed as inhibition of hemolysis
|
[PMID: 22677320] |
| Erythrocyte | EC50 |
96.625 μg/mL
Compound: Ascorbic acid
|
Hemolysis of human erythrocytes after 30 mins by spectrophotometry
Hemolysis of human erythrocytes after 30 mins by spectrophotometry
|
[PMID: 23811092] |
| HCT-116 | IC50 |
>100 μM
Compound: L-ASA
|
Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
| HEK293 | EC50 |
0.5 nM
Compound: Ascorbic acid
|
Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay
Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay
|
[PMID: 19243956] |
| HEK293 | EC50 |
156 μM
Compound: 54670067
|
Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810)
Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810)
|
10.5281/zenodo.7360349 |
| HeLa | IC50 |
>100 μM
Compound: L-ASA
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
| HepG2 | IC50 |
>100 μM
Compound: L-ASA
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
| HFF | IC50 |
>100 μM
Compound: L-ASA
|
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
| HL-60 | IC50 |
0.01 μM
Compound: Vitamin C
|
Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method
Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method
|
[PMID: 19555121] |
| HL-60 | IC50 |
10.2 μM
Compound: Vitamin C
|
Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay
Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay
|
[PMID: 16562834] |
| HL-60 | IC50 |
9.7 μM
Compound: Vitamin C
|
Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay
Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay
|
[PMID: 12762791] |
| J774.A1 | IC50 |
>100 μM
Compound: AA
|
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis
|
[PMID: 33422907] |
| MCF7 | IC50 |
>100 μM
Compound: L-ASA
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
| RD | EC50 |
>2270 μM
Compound: AA
|
Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 22390834] |
| SW-620 | IC50 |
>100 μM
Compound: L-ASA
|
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31586832] |
The anti-cancer effects of L-Ascorbic acid are determined by sodium-dependent vitamin C transporter 2 (SVCT-2), a transporter of L-ascorbic acid. L-Ascorbic acid (0.1 μM-2 mM) exhibits anti-cancer effects according to SVCT-2 expression and L-ascorbic acid uptake. Human colorectal cancer cell lines displays differential responses to L-ascorbic acid, primarily depending on the expression level of SVCT-2[4].
L-Ascorbic acid (10 μg/ml, 5 days) enhances the reprogramming of mouse fibroblasts into IPSCs[5].
L-Ascorbic acid (50 μg/ml, 9 days) promotes fibroblasts conversion into cardiomyocytes[6].
L-Ascorbic acid (50 ng/ml, 4-6 days) facilitates generation of all-iPS cell mice from terminally differentiated B cells[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 50-81-7
-
Appearance Solid
-
Molecular Weight 176.12
-
Formula C6H8O6
-
Color White to off-white
-
SMILES
OC([C@@]1([H])[C@H](CO)O)=C(O)C(O1)=O
-
Synonyms
L-Ascorbate (GMP Like); Vitamin C (GMP Like)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
DMSO : 100 mg/mL (567.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (567.79 mM; Need ultrasonic)
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Michael T Nelson, et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83. [Content Brief]
[2]. Aleksander Hinek, et al. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82. [Content Brief]
[3]. Sungrae Cho, et al. Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression. Sci Rep. 2018 Jul 27;8(1):11372. [Content Brief]
[4]. Satyanarayana Sreemantula, et al. Influence of antioxidant (L- ascorbic acid) on tolbutamide induced hypoglycaemia/antihyperglycaemia in normal and diabetic rats. BMC Endocr Disord. 2005 Mar 3;5(1):2. [Content Brief]
[5]. Sebastian J Padayatty, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003 Feb;22(1):18-35. [Content Brief]
[6]. Esteban MA, Wang T, Qin B, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2010;6(1):71-79. doi:10.1016/j.stem.2009.12.001 [Content Brief]
[7]. Talkhabi M, Pahlavan S, Aghdami N, Baharvand H. Ascorbic acid promotes the direct conversion of mouse fibroblasts into beating cardiomyocytes. Biochem Biophys Res Commun. 2015;463(4):699-705. [Content Brief]
[8]. Stadtfeld M, Apostolou E, Ferrari F, et al. Ascorbic acid prevents loss of Dlk1-Dio3 imprinting and facilitates generation of all-iPS cell mice from terminally differentiated B cells. Nat Genet. 2012;44(4):398-S2. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 5.6779 mL | 28.3897 mL | 56.7795 mL | 141.9487 mL |
| 5 mM | 1.1356 mL | 5.6779 mL | 11.3559 mL | 28.3897 mL | |
| 10 mM | 0.5678 mL | 2.8390 mL | 5.6779 mL | 14.1949 mL | |
| 15 mM | 0.3785 mL | 1.8926 mL | 3.7853 mL | 9.4632 mL | |
| 20 mM | 0.2839 mL | 1.4195 mL | 2.8390 mL | 7.0974 mL | |
| 25 mM | 0.2271 mL | 1.1356 mL | 2.2712 mL | 5.6779 mL | |
| 30 mM | 0.1893 mL | 0.9463 mL | 1.8926 mL | 4.7316 mL | |
| 40 mM | 0.1419 mL | 0.7097 mL | 1.4195 mL | 3.5487 mL | |
| 50 mM | 0.1136 mL | 0.5678 mL | 1.1356 mL | 2.8390 mL | |
| 60 mM | 0.0946 mL | 0.4732 mL | 0.9463 mL | 2.3658 mL | |
| 80 mM | 0.0710 mL | 0.3549 mL | 0.7097 mL | 1.7744 mL | |
| 100 mM | 0.0568 mL | 0.2839 mL | 0.5678 mL | 1.4195 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.